Search Results

There are 4796 results for: content related to: Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

  1. You have free access to this content
    Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

    Clinical and Experimental Pharmacology and Physiology

    Volume 42, Issue 10, October 2015, Pages: 999–1024, Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan and Shu-Feng Zhou

    Version of Record online : 15 SEP 2015, DOI: 10.1111/1440-1681.12455

  2. Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 5, May 2010, Pages: 463–484, Dr. Joshua J. Neumiller, Dr. Lindy Wood and Mr. R. Keith Campbell

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.30.5.463

  3. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 1, January 2011, Pages: 7–18, C. F. Deacon

    Version of Record online : 28 NOV 2010, DOI: 10.1111/j.1463-1326.2010.01306.x

  4. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 8, August 2010, Pages: 648–658, A. J. Scheen

    Version of Record online : 27 FEB 2010, DOI: 10.1111/j.1463-1326.2010.01212.x

  5. You have free access to this content
    Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis在亚洲人和白种人的2型糖尿病患者中DPP-4抑制剂的疗效及对β细胞功能的影响:一项meta分析

    Journal of Diabetes

    Volume 7, Issue 3, May 2015, Pages: 347–359, Xiaoling Cai, Xueyao Han, Yingying Luo and Linong Ji

    Version of Record online : 10 SEP 2014, DOI: 10.1111/1753-0407.12196

  6. You have free access to this content
    Implications of incretin-based therapies on cardiovascular disease

    International Journal of Clinical Practice

    Volume 69, Issue 5, May 2015, Pages: 531–549, M. E. Rotz, V. S. Ganetsky, S. Sen and T. F. Thomas

    Version of Record online : 1 NOV 2014, DOI: 10.1111/ijcp.12572

  7. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 10, October 2014, Pages: 891–899, T. M. E. Davis

    Version of Record online : 16 APR 2014, DOI: 10.1111/dom.12295

  8. You have free access to this content
    An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus

    Clinical and Experimental Pharmacology and Physiology

    Volume 42, Issue 12, December 2015, Pages: 1225–1238, Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan and Shu-Feng Zhou

    Version of Record online : 19 NOV 2015, DOI: 10.1111/1440-1681.12469

  9. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 7, July 2011, Pages: 594–603, K. Esposito, D. Cozzolino, G. Bellastella, M. I. Maiorino, P. Chiodini, A. Ceriello and D. Giugliano

    Version of Record online : 24 MAY 2011, DOI: 10.1111/j.1463-1326.2011.01380.x

  10. You have free access to this content
    Quantitative Model of the Relationship Between Dipeptidyl Peptidase-4 (DPP-4) Inhibition and Response: Meta-Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results

    The Journal of Clinical Pharmacology

    Volume 52, Issue 10, October 2012, Pages: 1494–1505, Dr John P. Gibbs, Dr Jill Fredrickson, Dr Todd Barbee, Ms Itzela Correa, Dr Brian Smith, Dr Shao-Lee Lin and Dr Megan A. Gibbs

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011420153

  11. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 12, December 2012, Pages: 1061–1072, K. Gooßen and S. Gräber

    Version of Record online : 17 MAY 2012, DOI: 10.1111/j.1463-1326.2012.01610.x

  12. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

    Diabetes/Metabolism Research and Reviews

    Volume 30, Issue 4, May 2014, Pages: 269–283, Paweł Kawalec, Alicja Mikrut and Sylwia Łopuch

    Version of Record online : 7 APR 2014, DOI: 10.1002/dmrr.2494

  13. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 3, March 2010, Pages: 224–233, Y. Moritoh, K. Takeuchi and M. Hazama

    Version of Record online : 22 SEP 2009, DOI: 10.1111/j.1463-1326.2009.01156.x

  14. You have free access to this content
    Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 1, January 2014, Pages: 30–37, D. Wu, L. Li and C. Liu

    Version of Record online : 16 JUL 2013, DOI: 10.1111/dom.12174

  15. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 10, October 2012, Pages: 927–936, Y. Seino, Y. Miyata, S. Hiroi, M. Hirayama and K. Kaku

    Version of Record online : 5 JUN 2012, DOI: 10.1111/j.1463-1326.2012.01620.x

  16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 2, February 2009, Pages: 167–176, R. E. Pratley, M. S. Kipnes, P. R. Fleck, C. Wilson, Q. Mekki and Alogliptin Study 007 Group

    Version of Record online : 29 DEC 2008, DOI: 10.1111/j.1463-1326.2008.01016.x

  17. You have free access to this content
    Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas

    Diabetes, Obesity and Metabolism

    Volume 18, Issue 4, April 2016, Pages: 333–347, C. F. Deacon and H. E. Lebovitz

    Version of Record online : 8 JAN 2016, DOI: 10.1111/dom.12610

  18. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

    Diabetes/Metabolism Research and Reviews

    Volume 27, Issue 4, May 2011, Pages: 362–372, Matteo Monami, Francesco Cremasco, Caterina Lamanna, Niccolò Marchionni and Edoardo Mannucci

    Version of Record online : 6 MAY 2011, DOI: 10.1002/dmrr.1184

  19. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 8, August 2012, Pages: 762–767, C. F. Deacon, E. Mannucci and B. Ahrén

    Version of Record online : 24 APR 2012, DOI: 10.1111/j.1463-1326.2012.01603.x

  20. Dipeptidyl Peptidase 4 Inhibitors

    Standard Article

    Burger's Medicinal Chemistry and Drug Discovery

    Ann E. Weber and Nancy A. Thornberry

    Published Online : 29 JAN 2010, DOI: 10.1002/0471266949.bmc183